Community curated by people like you

Vinay Prasad stories

Nov 12, 2026

FDA quietly shelves Trump's drug fast-track voucher program amid agency chaos

No new drugs have received a voucher under the FDA's fast-track review program since Marty Makary left the agency in May, with internal documents and sources indicating the program has been effectively abandoned amid ongoing agency turmoil.

Nov 12, 2026·2 sources

00

Top claims

▪Germany's Merck KGaA's fertility treatment Pergoveris remained unapproved three months after the FDA accepted its final application following an eight-month rolling review, as of November 2026
▪Former FDA Commissioner Marty Makary left the FDA in May 2026
▪No new drugs have received a Commissioner's National Priority Voucher since former FDA Commissioner Marty Makary left the FDA in May 2026

Topics

Drug pricing Drug Policy, Pricing & Approval Novo Nordisk Accelerated approval pathways Government and Regulatory Policy Pharmaceutical Industry Federal agencies Eli Lilly Trump administration FDA drug approval

Related entities